Priothera Secures EUR1.7 Million from Bpifrance for Rare Blood Cancer Program

Priothera, a biopharmaceutical company specializing in hematological malignancies, has been awarded nearly EUR1.7 million in non-dilutive funding through the i-Nov innovation competition. This French government initiative, part of the France 2030 strategy and administered by Bpifrance, supports Priothera’s clinical program aiming to evaluate the novel drug mocravimod as an adjunct to CAR-T cell therapies. Mocravimod, an oral sphingosine 1 phosphate (S1P) receptor modulator, could potentially reduce the severe toxic side effects associated with CAR-T therapy and improve its effectiveness in treating blood cancers like acute lymphoblastic leukemia and non-Hodgkin lymphoma. Priothera, operating between France and Dublin, is progressing its MO-TRANS global Phase 3 study, with aspirations of unlocking new therapeutic potentials across multiple blood cancer settings.